Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.76 |
| ▸ | IL1RN | P18510 | 1/20 | 0.76 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | UQCRB | P14927 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10895902 | 0.92 | KMT2A (0.77) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL810795 | 0.91 | KMT2A (0.91) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL9001182 | 0.87 | KMT2A (1.00) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL25031372 | 0.87 | KEAP1 (1.00) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| Phenyl(Phenylsulfonyl)Amine SCHEMBL114765 | 0.87 | KEAP1 (1.00) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL13167612 | 0.85 | KMT2A (0.80) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| Phenyl(Phenylsulfonyl)Amine SCHEMBL11513007 | 0.85 | KEAP1 (0.95) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| Phenyl(Phenylsulfonyl)Amine SCHEMBL6399560 | 0.85 | KEAP1 (0.95) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL3686387 | 0.83 | KMT2A (0.84) | KMT2AMEN1PKMALDH1A1KEAP1 | |
| SCHEMBL9001183 | 0.83 | KMT2A (0.84) | KMT2AMEN1PKMALDH1A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | THE CLEVELAND CLINIC FOUNDATION | 2016-11-03 | — | — | US | claimed |
| WO-2015095757-A1 | TREATMENT OF RETINOPATHY OF PREMATURITY (ROP) | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-06-25 | — | — | WO | claimed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-07-11 | — | — | US | claimed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | claimed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KMT2A 2350/4885MEN1 4467/4885PKM 1964/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KMT2A 2350/4885MEN1 4467/4885PKM 1964/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KMT2A 2350/4885MEN1 4467/4885PKM 1964/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | KMT2A 2002/4885MEN1 4223/4885PKM 1865/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | KMT2A 2350/4885MEN1 4467/4885PKM 1964/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | KMT2A 2002/4885MEN1 4223/4885PKM 1865/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | KMT2A 2350/4885MEN1 4467/4885PKM 1964/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | KMT2A 2951/4885MEN1 2544/4885PKM 913/4885 |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | VEGFA, ALDH1A2, PGF | KMT2A 2910/4885MEN1 4876/4885PKM 1719/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | KMT2A 1339/4885MEN1 4703/4885PKM 1441/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | KMT2A 2327/4885MEN1 2815/4885PKM 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.